First thing Monday morning, sell 3,100 shares of GENE and buy 90,000 shares of GTHP.
GTHP has a lower market cap and it has a real test for cancer.
Over 60M pap smears are taken annually in the US to test for cervical cancer.
GTHP developed a biophotonic test which is noninvasive, more accurate and does not require lab analysis.
It's already approved in the EU, Mexico, Canada .......
FDA approval is expected any day. The stock should triple on the announcement and continue climbing.
The market cap is only $20M.
Compare that to EXAS which got a colorectal cancer scan approved which requires poop to be sent to a lab.
It's market cap rocketed to $2 billion.
So, the upside is huge for GTHP.
The Hep C market is huge.
Over 60M pap smear tests are taken in the US annually.
GTHP's biophotonic scan is noninvasive, more accurate and produces instant test results.
or wait here years at ONCY for more failure.
The Hep C market is huge, some 60M pap smear tests are taken annually in the US.
GTHP has a biophotonic cervical cancer scan that is noninvasive, more accurate and produces instant test results.
International sales are ramping up (it's already approved in the EU, Canada, Mexico).
Expect partnership in the US after FDA aproval.
Great looking stock. International sales are ramping up. It's already approved in EU, Canada, Mexico.
Ludwick is trailer park trash.
He works out of a boiler room bathroom stall
SELL what he PUMPS.
Do the opposite of what he posts.
Ipso facto, load up on GTHP.
Thanks! Excellent call!!
These Pump & Dumpers are trying to scam the moms and pops.
Low market cap ... excellent time to buy.
EXAS recently got a colorectal cancer scan approved, their market cap rocketed to $2 billion!!!!!!!
GTHP at $20M has lots of upside.
The DUMP always follows.
Always go with late stage or approved, otherwise you are waiting for disappointment and dilution.
GTHP should get FDA approval for its cervical cancer scan any day.
Look for a triple on the announcement. The market cap is only $20M.
The market is huge and the profit on the disposable used in each scan is 90%.
GTHP will be an animal!!! Look for a buyout in the near future.
The new CEO is from GE Diagnostics and Abbott Healthcare.
GTHP is expected to get FDA approval for its biophotonic cervical cancer scan any day now.
The Hep C market is huge. Over 60M pap smear tests are taken annually in the US alone.
GTHP's scan is noninvasive, more accurate and produces instant test results.
This is a relatively risk free binary event. First, GTHP hasn't run up in price yet. The market cap is only $20M.
Second, the international market is larger than the US and they are already approved in the EU, Canada, Mexico, Singapore..... which makes US approval a slam dunk; but also, it means that GTHP is not dependent on US approval (the stock won't crash if FDA approval were to be denied). So there is huge upside and minimal downside.
How huge is the upside? EXAS, which recently got FDA approval for its colorectal cancer scan saw its market cap rocket to $2 BILLION. Again, GTHP is at a market cap of only $20 million.
GTHP's biophotonic technology is more advanced than EXAS's, which requires a poop sample to be sent to a lab for analysis. Biophotonics provides immediate test results, there's no need to wait for lab analysis and the additional expense that that entails.
International sales are starting to ramp up. An order was received from the Turkish Health Ministry. Distributors have been signed up. Units were shipped to Nigeria. The margins are nearly 90% for the disposables used in the scan. Once more units are placed at medical facilities, profits will come gushing in.
This is the time to buy as many shares as you can. Expect the stock price to climb and then GTHP to be bought out at a much much higher price. The new CEO is from GE Diagnostics and Abbott Healthcare.